Main Topics
Focused
Advances in disease biology
Advances in the management of B and T-cell lymphoid malignancies
Approaches to treating PV patients
AYA MPNs: pregnancy, thromboses, unique aspects
Cardiovascular assessment: how and when?
CAR therapies
Chemotherapy regimens
CHIP and inflammation in MPNs
Complications of the treatment of hematological diseases
Current clinical trials in MDS
Cytopenias
Essential thrombocytosis: state-of-the-art
FLT3 inhibitors
How to treat CALR ET – what about IPSET?
HR-MDS
Immunotherapy (eg. bispecific antibodies, cellular therapies, etc.)
Impact of new cellular therapy treatments: CAR-T cells
IPSS-M for MDS
Maintenance therapy for post allogeneic transplant in AML
Minimal residual disease monitoring and use in practice
Molecular monitoring
Myelofibrosis: current and novel approaches
NHL and CLL
Options for refractory diseases
Rare MPNs – focus on emerging subtypes
Role of future of pathology and molecular markers in MPNs
Therapeutic decisions based on MRD and AML
General
Choice of therapy for elderly and frail patients
Guidelines in specific clinical and rare situations
How targeted therapy can modify long-term outcome
Ongoing clinical trials and future trials
Outcome prediction and prognostication
Practical guidelines for the practicing physician
Role of new diagnostic strategies
The patients’ perspective